Evaluating blood clot risks in pancreatic cancer surgery
Venous Thromboembolism in Patients Undergoing Primary Pancreatic Tumour Resection; a Prospective Observational Study
This study is trying to see if certain blood tests can help predict the risk of blood clots in patients with pancreatic cancer who are having surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 64 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Thessaly Academic / other |
| Locations | 1 site (Larissa, Thessaly) |
| Trial ID | NCT05964621 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the development of venous thromboembolism (VTE) in patients with primary pancreatic cancer who are undergoing surgical resection. It will evaluate the predictive value of specific biomarkers and coagulation parameters obtained before or shortly after surgery to determine their association with VTE occurrence within 30 days post-operation. Additionally, the study will analyze the overall incidence of VTE in this patient population and assess their perioperative coagulation status.
Who should consider this trial
Good fit: Ideal candidates are patients with primary pancreatic cancer who are scheduled for surgical resection at the University Hospital of Larissa.
Not a fit: Patients with a history of recent thromboembolic events, bleeding disorders, or those with unresectable pancreatic cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk assessment and management strategies for preventing blood clots in pancreatic cancer patients undergoing surgery.
How similar studies have performed: While studies have explored thrombosis in cancer patients, this specific focus on pancreatic cancer and its unique prothrombotic state is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Consecutive pancreatic cancer patients undergoing pancreatic cancer resection in University Hospital of Larissa, after informed consent will be included. Exclusion Criteria: * Refuse to participate * Previous thromboembolic event \< 6 months prior to the operation * History of inherited or acquired bleeding disorder * ASA PS \> 3 * Concomitant presence of a second primary malignancy * Unresectable pancreatic cancer
Where this trial is running
Larissa, Thessaly
- University Hospital of Larissa — Larissa, Thessaly, Greece (Recruiting)
Study contacts
- Principal investigator: Dimitrios Zacharoulis, Professor — Dpt of Surgery
- Study coordinator: Eleni Arnaoutoglou, Professor
- Email: earnaout@gmail.com
- Phone: 6974301352
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.